Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimethyl malonate (DiMAL or DMM) is a small molecule research compound being investigated by the University of Aarhus for its cardioprotective effects. It acts as a prodrug that is hydrolyzed to malonate, which then functions as a competitive inhibitor of succinate dehydrogenase (SDH), also known as mitochondrial complex II. By blocking succinate oxidation, the compound reduces the accumulation of succinate during ischemia and the subsequent burst of reactive oxygen species (ROS) during reperfusion, thereby mitigating ischemia-reperfusion injury. Research at Aarhus University has focused on its potential to reduce infarct size in patients undergoing heart surgery, particularly comparing effects in diabetic versus non-diabetic cardiac tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimethyl malonate.